| The incidence of malignant tumors which has been doing serious harm to human life and health is increasing.among them, lung cancer is one of the most common malignant tumors . its high morbility and mortality still have increasing all over the world in recent years. In our country, the mortality of lung cancer is already jumped from the fourth to the first of various malignant tumors and especially in the village. And because our country is abundant in tobacco produce, the number of people who smoke is the most around the world (about 300 million). Especially the number of young people(including students of elementary and high school) who smoke is also increasing steadily, the incidence of lung cancer has a trend of low age, the number of small cell lung cancer﹑lung squamous carcinoma and lung adenocarcinoma are increasing obviously.Invasion and metastasis of maligant tumor are the main reasons for high mortality. Selectin family is one of cell adhesion molecules as a receptor molecule group which plays an important role in the inflammatory response, the formation of angiogenesis and the metastasis of many kinds of malignant tumors. E-SLT and P-SLT are the member of selectin family. At present, many experiments at home and abroad have already showed that E-SLT and P-SLT are high expression in the solid tumor of some organs, and the specific combination with ligands participate in invasion and metastasis of lung cancer.In our duty,using immunohistochemistry, the expression of P-SLT and E-SLT were studied in 68 lung cancer patients.We analyse the association between them with their clinicopathological parameters and suffer,s prognosis.Expecting to find a kind of index which can help us to judge the tumor,s benign or malignant, evaluate the state of illness, assess curative effect , suffer,s prognosis for clinic and provid a academic basis for the molecular target treatment of lung cancer.We selected a total 68 lung cancer patients who see a doctor in thoracic surgical department of China-Japan Union Hospital of Jilin University during a period from 1995 to 2005 as the research objects . There are 34 adenocarcinomas, 30 squamous cell carcinomas and 4 small cell carcinomas. The gender distribution was 36 men and 32 women. The mean age was 58.26±8.64 years old,with the range from 42 to 70 years old . According to TNM classification of lung cancer United States and the International Union Against Cancer Committee in 2002 enacted, 38 patients in stage I to II, 30 patients in stage III.By pathological cancer differentiation,the medium and high differentiation group was 36,the poor differentiation group was 28.All patients has no history of chemotherapy and radiotherapy.And some patients with follow-up investigation,the follow-up time is the date of the surgery, the survival time is the time for death with metastasis, spreading or recurrence. We have gained the follow-up information of 46 patients.Among them,there are 45 cases of non-small cell lung cancer.Results:1.Expression of P-SLT in Lung cancer:(1)The expression and localization of P-SLT was buffy or tawny in the stromal tumor vascular endothelial cell.We have seen the expression of varying degrees in stromal tumor vascular endothelial cell in the lung adenocarcinoma, squamous cell carcinoma.There was no expression in SCLC(4 cases of small cell lung cancer no positive response). However, duing to small-cell lung cancer specimens were little, we need further research to confirm the credibility of the results.(2)The positive rate of P-SLT in NSCLC was 40.62% (26/64),in adenocarcinoma was 61.76% (21/34) significantly higher than that in squamous cell carcinoma,16.67% (5/30),the difference was statistical significant (P <0.05).(3)The positive rate of P-SLT in stage I-II of lung cancer was 22.22%(8/36),in stage III was 64.28%(18/28), the difference was statistical significant (P <0.05).(4)There was no correlation between the expression of P-SLT with the patient's age, sex, the degree of tumor differentiation and clinical stages in adenocarcinoma and squamous cell carcinoma, there was no statistical significant difference (P> 0.05).2. Expression of E-SLT in lung cancer:(1)The expression and localization of E-SLT was buffy or tawny in the stromal tumor vascular endothelial cell .there were varing degrees expression in the stromal tumor vascular endothelial cell in the lung adenocarcinoma, squamous cell carcinoma.There was weak expression in SCLC(only one case is positive in four cases of SCLC).(2) The positive rate of E-SLT in NSCLC was 62.50% (40/64).The positive rate in lung adenocarcinoma was76.47% (26/34), significantly higher than that in squamous cell carcinomas 46.67%(14/30), there was statistical significant differences (P <0.05).(3)The positive rate of E-SLT in stage I-II of lung cancer was44.44% (16/36 ), in stage III was 85.71% (24/28) , the difference was statistical significant (P <0.05).(4)The positive rate in group of poor differentiation was 78.57%(22/28),in medium and high differentiation was 50%(18/36), the difference was statistical significant (P <0.05).(5)the positive rate of E-SLT in female patients 73.33% (22/28) was rather higher than that in male patients 52.94% (18/34), there was statistical significant differences (P <0.05).(6) There was no correlation between the expression of E-SLT with the patient's age.3.The patients with positive expression of P-SLT whose average survival time was significantly lower than that with negative expression of P-SLT. The patients with positive expression of E-SLT whose average survival time was significantly lower than that with negative expression of E-SLT,the difference was significant (P <0.05).The patients with positive expression of both P-SLT and E-SLTwhose mean survival time was significantly reducer than that with the one positive antigen and two negative antigens. There was significant difference (P <0.05).To sum up, we can conclude: Comparing P-SLT and E-SLT in the patients with the same TNM stage of lung squamous carcinoma and lung adenocarcinoma, the above two indicators of patients in lung adenocarcinoma is higher and the result have statistic significance. We presume that it may be related to blood vessel-rich with adenocarcinoma, local infitration and metastasis earlier and its malignancy relatively higher than squamous cell carcinoma.The expression of E-SLT in the stage III of pulmonary adenocarcinoma﹑squamous cell carcinoma was significantly higher than that in the stage I-II,and the expression of E-SLT in poorly differentiated lung cancer was higher than that in the well differentiated lung cancer.The result suggests that the E-SLT has relation with the tumor grade and stage in NSCLC;Moreover,it is worth noting that non-small cell lung cancer(squamous cell carcinoma,adenocarcinoma) patients,the group of men and women were theated with statistic means,the positive rate of women were significantly higher than men,the difference was significant (P<0.05). One hand,the exoression of E-SLT may be related to gender,the orther hand,the patients of adenocarcinoma was a little more in women group,and may also be related to the type of lung cancer.But the positive rate of P-SLT was not related to gender.In addition,our experiment indicated that there was an association between the expression of P-SLT and the expression of E-SLT in NSCLC.Whether P-SLT or E-SLT with positive expression in patients whose average survival time was significantly lower than negative expression,and the average survival time with positive expression of P-SLT is obviously lower than positive expression of E-SLT.The average survival time of the patients with positive expression of both antigens is the lowest. It suggests that those antigens might have synergistic effect in the development of NSCLC.With the research of expression of P-SLT and E-SLT in lung cancer(squamous cell carcinoma and adenocarcinoma mainly) suggests that P-SLT and E-SLT in play an important role tumor occurrence and development and can be used as new indicators for the prognosis for lung cancer and can provide a new sight for the target treatment of lung cancer.In view of this,we can take measures to contain or block the way for P-SLT or E-SLT and their corresponding ligand,and contain the adhesion way from lung cancer cells to endothelial cells and platelat,in order to curb the incidence and development of tumors.
|
PDF Full Text Request